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Chemotherapy has been regarded as standard therapy for the majority of women with advanced epithelial ovarian cancer for several
decades, with this role filled largely by the alkylating agents — used as monotherapy — until the mid-1980s. The activity of cisplatin in
this disorder was established during the 1970s, and combinations of cisplatin and an alkylating agent were widely used during the late
1980s. However, further research prompted by continuing concerns over poor survival and tolerability led to the adoption of
paclitaxel in combination with either cisplatin or carboplatin as first-line therapy in ovarian cancer during the 1990s. Most recent
research has focused on further optimisation of these regimens to maximise clinical benefit while minimising toxicity, and
investigations into alternative taxanes (e.g. docetaxel), other novel agents and new treatment schedules are ongoing.
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EPIDEMIOLOGY AND DISEASE SYMPTOMS
Despite advances in treatment over the last 40 years, ovarian
cancer is the second most commonly diagnosed gynaecological
malignancy, and causes more deaths than any other cancer of the
reproductive system. Over 25400 new cases and 14300 deaths were
expected in the USA alone in 2001 (American Cancer Society,
2003).
Epithelial ovarian cancer is the most common histological
type: at least 80% of tumours arise from the coelomic epithelium,
of which 75% are serous crystadenocarcinomas. Other less
common types include mucinous, endometroid, transitional cell,
Brenner, clear cell and unclassified carcinomas. The remaining
20% are germ-cell and sex cord-stromal cell tumours, and those
associated with metastatic spread to the ovaries (Beers and
Berkow, 1999).
Ovarian cancer is not easily diagnosed because the most
common presenting symptoms of persistent abdominal
distension — pain and pressure in the pelvis — can be attributed
to a number of causes (Lister-Sharp et al, 2000). Patients may
be asymptomatic until an abdominal mass is discovered
during routine pelvic examination or until the tumour has
metastasised (Memarzadeh and Berek, 2001); consequently,
progression to late stage before diagnosis is seen in the majority
of presenting women. Approximately 75% of patients are at
International Federation of Gynecology and Obstetrics (FIGO)
stages II–IV at the time of diagnosis (Beers and Berkow, 1999;
Lister-Sharp et al, 2000).
In women with low-risk stage I epithelial ovarian cancer, 5-year
survival rates can be as high as 90% (Memarzadeh and Berek,
2001); however, these rates fall progressively as the disease
becomes more advanced (to 11% in patients with stage IV
malignancy).
SURGERY AND CHEMOTHERAPY FOR OVARIAN
CANCER
Surgery is currently the intervention of first choice in ovarian
cancer (Lister-Sharp et al, 2000). Comprehensive surgical staging
is indicated if malignancy is suspected or confirmed, with
omentectomy and sampling of pelvic and para-aortic lymph nodes
(Beers and Berkow, 1999; National Cancer Institute (NCI), 2002).
Hysterectomy with bilateral salpingo-oophorectomy is usually
indicated and in young patients with low-grade unilateral epithelial
lesions or nonepithelial malignancy, reproductive capability can be
preserved by the excision of the affected ovary only (with
completion of surgical staging procedures). However, in advanced
cases, tumour debulking is recommended to improve the efficacy
of adjunctive therapies (Beers and Berkow, 1999). Optimal
debulking can be achieved in the majority of patients, and
prognosis is directly related to the success of such cytoreductive
surgery (Beers and Berkow, 1999; Memarzadeh and Berek, 2001).
Chemotherapy for ovarian cancer has progressed considerably
over the past two decades, with treatment for advanced disease
moving from the use of alkylating agents to current recommended
regimens based on taxanes and platinum compounds. (Dunton,
1997; Lister-Sharp et al, 2000; Memarzadeh and Berek, 2001). This
review summarises the history of chemotherapy in ovarian
epithelial cancer (major events from the mid-1980s to the present
day are illustrated in Figure 1), and discusses the development of
the regimens currently used in clinical practice.
HISTORY OF CHEMOTHERAPY
Twenty years ago, women with advanced ovarian cancer were
treated most commonly with the alkylating agents melphalan,
cyclophosphamide, chlorambucil and thiotepa — all as mono-
therapy. These drugs were associated with overall objective
response rates ranging between 33 and 65%, with complete clinical
responses being seen in approximately 20% of patients (Young *Correspondence: Dr WP McGuire III; E-mail: wmcguire52@aol.com
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was approximately 17–20 months (Dunton, 1997).
A series of studies carried out from the mid-1970s onwards
established cisplatin as one of the most active agents available for
ovarian cancer, with Wiltshaw and Kroner (1976) reporting an
overall response rate of 26.5% in 34 patients resistant to alkylating
agents. Similarly, Young et al (1979) obtained objective responses
(one of which was complete) in 29% of 25 patients refractory to
alkylating agents. In 1985, the North Thames Cooperative Group
reported the results of the first randomised comparison of first-
line single-agent cisplatin with an alkylating agent (cyclopho-
sphamide) in 86 women with advanced ovarian cancer, and
showed significantly longer survival and response duration in
patients receiving platinum therapy (Lambert and Berry, 1985).
After the publication of these results and other data showing
superior response rates and survival with combination over single-
agent therapy (Neijt et al, 1984; Williams et al, 1985; Omura et al,
1986; Advanced Ovarian Cancer Trialists’ Group, 2000), combina-
tions of cisplatin with an alkylating agent became established as
standard treatment.
Further analysis indicated a possible clinical benefit from the
addition of an anthracycline to cisplatin–alkylating agent regi-
mens. A meta-analysis of data from 10 trials in 1702 patients
(A’Hern and Gore, 1995), five of which compared cyclopho-
sphamide plus cisplatin (CP) with cyclophosphamide, cisplatin
and doxorubicin (CAP), showed a modest — but significant —
improvement in survival for the doxorubicin regimens (overall
hazard ratio 0.85; P¼0.003). The potential benefit obtained from
the addition of anthracyclines has since intrigued research groups,
and CAP regimens are the basis of two large-scale trials discussed
in later sections of this paper (International Collaborative Ovarian
Neoplasm (ICON) Collaborators, 1998; ICON Group, 2002). Most
investigators in the United States abandoned anthracyclines in
1986 due to concerns that the cardiotoxicity outweighed the
clinical benefit.
A retrospective review reporting a significant correlation
between the dose intensity of cisplatin and response rates and
survival in women with ovarian cancer (Levin and Hryniuk, 1987;
see McGuire, 2000 for further details) prompted a series of dose-
intense chemotherapy studies. Such studies were conducted with
the aim of further improving platinum-based chemotherapy and
minimising the emergence of drug resistance. Overall, data from 10
trials focusing on platinum agents in nearly 2000 patients
suggested improvements in outcomes with dosages of up to
25mgm
 2week
 1, with increasing toxicity but no further clinical
benefit above that level observed (McGuire, 2000). Of related
interest is intraperitoneal chemotherapy, which offers the potential
advantage of exposing tumour cells to higher localised doses of
chemotherapy than would be possible with systemic administra-
tion. The results of clinical trials carried out to date are
inconclusive, however, and the place of high-dose or intraper-
itoneal chemotherapy in the treatment of ovarian cancer remains
under investigation (McGuire, 2000; Kaye, 2001).
The emergence of taxane-based combinations
A significant development in the search for more effective
chemotherapeutic drugs in the treatment of ovarian cancer was
the discovery of the taxane class. The taxanes were originally
derived from the bark of the Pacific Yew tree, Taxus brevifolia, and
paclitaxel was identified as the active constituent in 1971.
Docetaxel, introduced later, is a semisynthetic taxoid derived
from the needles of T. baccata (Lister-Sharp et al, 2000). These
agents promote the assembly of microtubules and inhibit
depolymerisation; and this action (unique to the taxanes) disturbs
mitosis in normal and malignant cells (Schiff et al, 1979). Early
studies carried out in the late 1980s and early 1990s in 70 evaluable
patients showed encouraging activity (overall response rates of
25–30%) of paclitaxel against advanced refractory ovarian
epithelial cancer (McGuire et al, 1989; Einzig et al, 1992).
Two randomised, controlled trials of first-line cisplatin-based
dual therapy showed additional clinical benefit when cyclopho-
sphamide was replaced by paclitaxel. The Gynecologic Oncology
Group (GOG) 111 trial studied 386 women with stage III
suboptimally debulked or stage IV disease (McGuire et al, 1996),
whereas the Intergroup OV10 trial had wider selection criteria and
assessed 675 women with FIGO stage IIb, IIc, III or IV disease with
or without successful debulking (Piccart et al, 2000). Patients in
both studies had received no prior radio- or chemotherapy.
Patients in GOG 111 received cisplatin 75mgm
 2 plus paclitaxel
135mgm
 2 over 24h or cyclophosphamide 750mgm
 2 every 3
weeks for a total of six courses. The same drugs were compared in
OV10, except that paclitaxel 175mgm
 2 was infused over 3h and
up to nine 3-weekly cycles were given. The median follow-up
periods were 37 and 38.5 months in the GOG 111 and OV10
studies, respectively.
As shown in Table 1, both studies showed statistically significant
improvements in the median overall and progression-free survival
when paclitaxel was used in place of cyclophosphamide. Overall
survival improvements were particularly impressive, with pacli-
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Figure 1 Evolution of chemotherapy for advanced ovarian cancer from the mid-1980s.
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than those who received cyclophosphamide. In addition, complete
clinical responses were obtained with paclitaxel plus cisplatin in
statistically significantly greater proportions of evaluable patients
in both studies (Table 1).
However, these improvements with paclitaxel were accompanied
by increased toxicity. The incidence of neutropenia, febrile
neutropenia, alopecia and peripheral neurotoxicity were signifi-
cantly (Pp0.05) higher overall in the paclitaxel-treated group in
GOG 111. While grade III/IV neutropenia and febrile neutropenia
were noted, alopecia and peripheral neurotoxicity were grade II/III
events. In addition, substantially more patients in the paclitaxel-
than the cyclophosphamide-treated group in OV10 experienced
severe myalgia, neurosensory and neuromotor symptoms, alopecia
and hypersensitivity reactions. The 3-h paclitaxel infusion used in
this study resulted in grade III or IV neurosensory and grade III
neuromotor toxicity in 19.6 and 5% of patients, respectively,
relative to 1 and 0.6% in the cyclophosphamide/cisplatin group.
The levels of neurotoxicity with this 3-h infusion regimen were
considerably higher than those seen with the 24-h infusion used in
GOG 111 (grades III–IV neurological symptoms in 4% of
patients).
Carboplatin as a substitute for cisplatin
Cisplatin is associated with significant neurotoxicity, ototoxicity,
nephrotoxicity and gastrointestinal toxicity in addition to myelo-
suppression, and the substantial toxicity seen in patients receiving
this agent in combination with paclitaxel prompted investigations
to evaluate carboplatin as an alternative taxane partner. The
tolerability advantages of carboplatin rapidly became evident after
its introduction in 1985; and the place of the drug in the
management of ovarian cancer was solidified in 1998 by
publication of a meta-analysis of 37 trials in over 5000 patients
that showed (i) superiority of platinum- over nonplatinum-based
treatment and (ii) equivalent efficacy of cisplatin and carboplatin
(Aabo et al, 1998).
The addition of carboplatin rather than cisplatin to a taxane was
expected to result in reductions in the incidence and severity of
emesis and neurotoxicity — possibly with increased levels of
myelosuppression. Accordingly, regimens containing carboplatin
and paclitaxel were generally better tolerated than cisplatin plus
paclitaxel in three major studies in which the two doublets showed
similar efficacy (Table 2). The Dutch/Danish study (Neijt et al,
2000) in 208 patients and the Arbeitsgemeinschaft Gynaekolo-
gische Onkologie (AGO) study (du Bois et al, 2003) in 798 patients
compared 3-weekly paclitaxel 175 or 185mgm
 2 infused over 3h
plus cisplatin 75mgm
 2 with the same dosage of paclitaxel plus
carboplatin infused to achieve AUC 5 or 6. Women in both studies
had stage IIb–IV disease and were followed up for a median of 37
months (Neijt et al, 2000) or a mean of 49–50 months (du Bois
et al, 2003). The GOG 158 trial in 792 eligible patients with optimal
stage III disease compared paclitaxel 135mgm
 2 infused over 24h
plus cisplatin 75mgm
 2 with paclitaxel 175mgm
 2 over 3h plus
carboplatin to AUC 7.5 (Ozols et al, 2003).
The final results from AGO, GOG 158 and the Dutch/Danish
study showed little difference between treatments in the median
progression-free survival (see Table 2 for summary of available
data). Although the median overall survival was similar between
treatment arms in each study, it was higher among patients in the
AGO and GOG 158 studies — ranging between 44 and 57 months
— compared with 30 months of the Dutch/Danish study. Toxicity
profiles were mainly as expected, with paclitaxel plus carboplatin
being better tolerated overall. The Dutch/Danish investigators
(Neijt et al, 2000) reported more grade III or IV granulocytopenia
with paclitaxel plus carboplatin than with paclitaxel plus cisplatin,
but nonhaematological toxicities — in particular neurotoxicity —
were less frequent with carboplatin (Figure 2). Patient numbers in
this study were too small for definitive conclusions to be drawn,
but the larger AGO study (du Bois et al, 2003) also showed more
frequent but statistically nonsignificant haematological toxicity
with carboplatin and more nonhaematological toxicity with
cisplatin (grades III–IV peripheral neuropathy in 8% of patients
in the carboplatin arm and in 19% of cisplatin recipients). To date,
more grade IV leucopenia, grades III–IV gastrointestinal toxicity,
fever and metabolic toxicity have been reported in GOG 158 with
24-h paclitaxel plus cisplatin than with 3-h paclitaxel plus
carboplatin, with more thrombocytopenia and pain (probably
due to paclitaxel-associated arthralgias) in carboplatin recipients
as well as a statistically greater incidence of grade III/IV
Table 1 Clinical response and survival in the GOG 111
a and OV10
b studies
No. of patients evaluable
for clinical response
Overall response
rate (%)
Complete response
rate (%)
Median progression-
free survival (months)
Overall median
survival (months)
Treatment arm GOG 111 OV10 GOG 111 OV10 GOG 111 OV10 GOG 111 OV10 GOG 111 OV10
Cisplatin+paclitaxel 100 162 73 58.6* 51* 40.7* 18* 15.5* 38* 35.6*
Cisplatin+cyclophosphamide 116 161 50 44.7 31 27.3 13 11.5 24 25.8
aCisplatin 75mgm
 2+either paclitaxel 135mgm
 2 over 24h or cyclophosphamide 750mgm
 2 every 3 weeks (McGuire et al, 1996).
bCisplatin 75mgm
 2+either paclitaxel
175mgm
 2 over 3h or cyclophosphamide 750mgm
 2 every 3 weeks (Piccart et al, 2000). *Statistically significant difference between treatments (Po0.05).
Table 2 Clinical response and survival in studies comparing 3-weekly paclitaxel plus cisplatin with paclitaxel plus carboplatin. Final results of the Dutch/
Danish study,
a the AGO
b and GOG 158
c trials
No. of patients evaluable
for clinical response
Overall response
rate (%)
Complete response
rate (%)
Median progression-
free survival (months)
Overall median
survival (months)
Treatment
arm
Dutch/
Danish AGO
Dutch/
Danish AGO
Dutch/
Danish AGO
Dutch/
Danish AGO GOG 158
Dutch/
Danish AGO GOG 158
Paclitaxel+cisplatin 65 75 62 81.4 35 38.7 16 19.1 19.4 30 44.1 48.7
Paclitaxel+carboplatin 67 99 66 67.7 40 31.3 16 17.2 20.7 32 43.3 57.4
aPaclitaxel 175mgm
 2 over 3h+either cisplatin 75mgm
 2 or carboplatin to AUC 5 (Neijt et al, 2000).
bPaclitaxel 185mgm
 2 over 3h+either cisplatin 75mgm
 2 or
carboplatin to AUC 6 (du Bois et al, 2003).
cPaclitaxel 135mgm
 2 over 24h+cisplatin 75mgm
 2 or paclitaxel 175mgm
 2 over 3h+carboplatin to AUC 7.5 (Ozols et al, 2003).
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carboplatin was escalated to 7.5 (Ozols et al, 2003).
The optimal taxane platinum regimen
The encouraging results obtained to date with taxane–platinum
regimens have prompted further research to resolve outstanding
issues; several trials, including GOG 132 (Muggia et al, 2000) and
the second and third International Collaborative Ovarian Neo-
plasm group studies (ICON-2; ICON-3), have provided further
insight (ICON Collaborators, 1998; ICON Group, 2002).
GOG 132 was a three-arm trial of 3-weekly paclitaxel 135mgm
 2
over 24h plus cisplatin 75mgm
 2 compared with high-dose
cisplatin (100mgm
 2) or paclitaxel (200mgm
 2 over 24h) alone,
each for six cycles, in 614 patients (Muggia et al, 2000). As shown
in Table 3, the results showed no significant difference in the
median overall survival among treatment arms; however, cisplatin
alone or in combination yielded superior response rates and
progression-free survival. In addition, the combination of
paclitaxel and cisplatin was better tolerated overall than cisplatin
alone. Neutropenia, fever and alopecia were more frequent and
severe with the paclitaxel regimens than with cisplatin alone
(Po0.001), and neutropenia (P¼0.008) and febrile episodes
(Po0.001) tended to be more severe with paclitaxel monotherapy
than with the combination regimen. Not only were anaemia,
thrombocytopenia and gastrointestinal toxicity more frequent and
severe (Po0.001) in the cisplatin groups, but renal toxicity was
also most severe (Po0.001) and there was a tendency for more
frequent and severe neurotoxicity in the cisplatin monotherapy
group. Both monotherapies were discontinued more frequently
than the combination: 17% of patients withdrew from cisplatin
treatment resulting from toxicity or patient refusal vs 7% in the
combination group, and 20% withdrew from paclitaxel mono-
therapy because of early disease progression compared with 6% in
the combination group.
It was suggested that the similarity in overall survival across
treatment arms may have been related to the frequency of
treatment crossover in this study, particularly from cisplatin
monotherapy to paclitaxel. The similarity between results in the
initial cisplatin and combination arms suggests that sequential
therapy may confer benefit. No conclusions in this respect could
be drawn; however, since GOG 132 was not designed or powered to
show such an effect. Further studies will be needed to clarify this
point. The authors concluded that on the basis of these results,
taxane/platinum combination therapy should remain the preferred
first-line option in advanced ovarian cancer.
If sequential therapy involving taxanes and platinums is to be
developed, the ICON trials provide interesting data, suggesting that
single-agent carboplatin should be considered in this setting.
ICON-2 compared 3-weekly carboplatin monotherapy (to achieve
AUC 5) with a CAP regimen comprising cyclophosphamide
500mgm
 2, doxorubicin 50mgm
 2 and cisplatin 50mgm
 2, both
for six cycles, in 1526 patients from 132 hospitals (ICON
Collaborators, 1998). There was no difference in survival between
the two groups (median progression-free survivals was 15.5 and 17
months for carboplatin and CAP, respectively, with a median
overall survival of 33 months in both groups), and there was no
evidence of any difference in efficacy in any subgroup of patients
(e.g. age, FIGO stage, residual tumour bulk and histology).
However, CAP was substantially more toxic than carboplatin,
causing more alopecia, leucopenia and nausea (detailed toxicity
data were available for patients attending Italian centres only;
major events are shown in Figure 3).
ICON-3 can be viewed as two parallel randomised trials
comparing carboplatin alone with carboplatin plus paclitaxel,
and carboplatin plus paclitaxel with CAP in a total of 2074 patients
(ICON Group, 2002). Paclitaxel was given at a dose of 175mgm
 2
by 3-h infusion but depending on the method used to determine
glomerular filtration rate (GFR), the carboplatin dose was a
minimum of either AUC 5(GFRþ25) or 6(GFRþ25)mg. All
regimens were administered every 3 weeks for up to six cycles. The
final results, for a median follow-up of 51 months, showed no
significant differences in overall survival between carboplatin plus
paclitaxel and carboplatin alone or CAP (hazard ratio 0.98;
P¼0.74), which does not appear to concur with the positive
results reported for cisplatin plus paclitaxel in GOG 111 (McGuire
et al, 1996) and OV10 (Piccart et al, 2000). However, ICON-3
recruited a wide range of patient types — disease stages I–IV, with
46% of patients with residual tumour bulk X2cm, 30% with no or
microscopic disease and 55% with poorly differentiated disease
(ICON Group, 2002). Although no statistically significant differ-
ences were seen in patients treated with or without paclitaxel, an
early trend towards overall survival benefit was noted in favour of
paclitaxel plus carboplatin, from between 12 and 36 months from
randomisation in patients with residual tumour bulk X2cm. It
was noted that approximately one-third of patients in the control
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Figure 2 Incidence of adverse events showing differences between
treatment arms in the Dutch/Danish study of 3-weekly paclitaxel
175mgm
 2 infused over 3h plus either cisplatin 75mgm
 2 or carboplatin
infused to achieve AUC 5 (Neijt et al, 2000).
Table 3 Summary of clinical results from the GOG 132 study of 3-weekly paclitaxel 135mgm
 2 over 24h plus cisplatin 75mgm
 2 compared with
cisplatin alone (100mgm
 2) or paclitaxel alone (200mgm
 2 over 24h), each for six cycles (Muggia et al, 2000)
Treatment arm
No. of patients evaluable
for clinical response
Overall response
rate (%)
Complete response
rate (%)
Median progression-
free survival (months)
Median overall
survival (months)
Cisplatin 122 67* 42 16.4* 30.2
Paclitaxel 131 42* 21 10.8* 25.9
Cisplatin+paclitaxel 124 67* 43 14.1* 26.3
*Statistically significant difference between treatments (Po0.05).
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platinum), mainly after disease progression. Therefore, it seems
possible that the efficacy of taxanes and platinum agents, together
or as monotherapy, may depend at least in part on the manner in
which they are sequenced, and it may be desirable to investigate
and specify further the optimum way in which to use the taxanes.
Taxanes as continuation therapy
Of additional interest is the observation of the prolongation of
progression-free survival with the use of continuation therapy with
single-agent paclitaxel after complete response to platinum/
paclitaxel therapy (Markman et al, 2002). A total of 277
patients with advanced ovarian cancer were randomised to either
3 or 12 months follow-on treatment with paclitaxel (initially
175mgm
 2 every 28 days, subsequently reduced to 135mgm
 2
because of concerns regarding a higher drop-out rate in the
12-month arm).
The improvement in the 12-month arm was sufficiently
compelling for this trial to be terminated early. The median
progression-free survival in the 3- and 12-month groups was 21
and 28 months, respectively (P¼0.0023 by adjusted Cox model
analysis), with a 3- vs 12-cycle progression hazard ratio of 2.31.
However, there was no significant difference between groups in the
median overall survival at the date of study closure.
CONCLUSIONS
For several decades, chemotherapy has been the mainstay of
treatment in all but early-stage and well-differentiated malignant
ovarian tumours; the literature shows a clear progression from a
dependence on alkylating agents to the platinum-based regimens
in use today. Results of numerous randomised-controlled trials
have pointed to taxane–platinum combinations as the standard of
care for women with advanced ovarian cancer, and these are now
generally recommended for first-line treatment (Lister-Sharp et al,
2000). There is currently no call for a change in this recommenda-
tion (Tattersall, 2002), although the availability of mature data
from the ICON-3 trial offers an opportunity for review and
refinement of treatment guidelines.
Despite the progress discussed in this review, most patients with
advanced ovarian cancer eventually die from their disease. Further
improvements in toxicity, response rates and survival may result
from the use of an alternative taxane such as docetaxel, from the
incorporation of other agents or from the use of different
treatment schedules. Agents of particular interest in this respect
include topotecan, gemcitabine, epirubicin, liposomal doxorubi-
cin, etoposide and oxaliplatin, and it is expected that ongoing
research will contribute to the improvement of outcomes as the
chemotherapy of advanced ovarian cancer continues to develop.
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